In Q1 FY2026 (ended March 31, 2026), Viridian Therapeutics reported revenue of $141,000, a 95.8% increase year-over-year. Net loss widened to $104.9 million, and operating loss was $116.2 million. Diluted EPS was -$1.15. The company had $636.0 million in equity and $20.9 million in long-term debt.
•Revenue rose 95.8% YoY to $141,000.
•Net loss increased 20.7% to $104.9 million.
•Operating loss grew 23.8% to $116.2 million.
•Equity stood at $636.0 million; long-term debt was $20.9 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Viridian Therapeutics discovers, develops, and commercializs treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. It also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.
Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. Incorporated in 2010 and headquartered in Waltham, Massachusetts, Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. before rebranding in January 2021.
Viridian Therapeutics is a biotechnology company focused on discovering, developing, and commercializing treatments for serious and rare diseases. Its primary area of focus is thyroid eye disease (TED), for which it is developing IGF-1R therapies. The company's lead product candidates include Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R administered intravenously, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R therapy. Additionally, Viridian is developing an anti-thyroid-stimulating hormone receptor (TSHR) candidate for Graves' disease and TED. The company also has a portfolio of engineered inhibitors of the neonatal Fc receptor (FcRn), including VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor designed to prolong IgG suppression. Viridian was formerly known as Miragen Therapeutics before rebranding in January 2021.
Where is Viridian Therapeutics (VRDN) listed and what currency does it trade in?
Viridian Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol VRDN. The company trades in US dollars (USD), as it is headquartered in the United States and its stock is traded on a US-based exchange. The NasdaqCM is part of the Nasdaq stock exchange, which is one of the major stock exchanges in the world, primarily listing technology and biotechnology companies. Investors can buy and sell shares of Viridian Therapeutics in USD through brokerage accounts that have access to US markets.
What sector and industry does Viridian Therapeutics (VRDN) belong to?
Viridian Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing therapies for serious and rare diseases, particularly in the areas of endocrinology and immunology. The company's work involves monoclonal antibodies and other biologic drugs targeting specific receptors like IGF-1R and FcRn. Biotechnology companies like Viridian typically engage in high-risk, high-reward drug development, with products often requiring extensive clinical trials and regulatory approvals before reaching the market.
Where is Viridian Therapeutics (VRDN) headquartered and what is its history?
Viridian Therapeutics is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2010 and was originally known as Miragen Therapeutics, Inc. before rebranding to Viridian Therapeutics in January 2021. This rebranding likely reflected a shift in strategic focus from its earlier work to its current emphasis on thyroid eye disease and FcRn inhibitors. Waltham is part of the greater Boston area, a major hub for biotechnology and pharmaceutical research, providing access to talent, research institutions, and funding opportunities.
What are the main product candidates in Viridian Therapeutics' (VRDN) pipeline?
Viridian Therapeutics' pipeline is centered on therapies for thyroid eye disease (TED) and other autoimmune conditions. Its key product candidates include Veligrotrug, a humanized monoclonal antibody targeting IGF-1R administered intravenously, and Elegrobart, a subcutaneous formulation of an IGF-1R inhibitor designed for low-volume, infrequent dosing. The company is also developing an anti-thyroid-stimulating hormone receptor (TSHR) candidate for Graves' disease and TED. In addition, Viridian has a portfolio of FcRn inhibitors: VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor that combines an Fc fragment with an albumin-binding domain to prolong IgG suppression. These candidates target serious and rare diseases with significant unmet medical needs.